LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Written by

admin

in

  • Results presented at the 17th World Stroke Congress (WSC 2025)
  • LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial hemorrhage…

Continue Reading

More posts